Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Bellicum Pharmaceuticals Stock Forecast NASDAQ:BLCM
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-02-16 | 242.47% | Ladenburg Thalmann | $5.00 | Initiates Coverage On | Buy |
| 2020-10-30 | 208.22% | Wells Fargo | $4.50 | Downgrades | Overweight Equal-Weight |
| 2020-03-13 | 1064.38% | Raymond James | $40.00 $17.00 | Maintains | Outperform |
BLCM Stock Trend
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
Given the current short-term trend, the stock is expected to fall -15.71% during the next 3 months and, with a 90% probability hold a price between $1.07 and $1.63 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-06-01 | $1.26 | $1.60 | $1.93 |
| 2022-06-02 | $1.26 | $1.59 | $1.92 |
| 2022-06-03 | $1.25 | $1.58 | $1.91 |
| 2022-06-06 | $1.25 | $1.58 | $1.91 |
| 2022-06-07 | $1.24 | $1.57 | $1.90 |
| 2022-06-08 | $1.24 | $1.57 | $1.90 |
| 2022-06-09 | $1.23 | $1.56 | $1.89 |
| 2022-06-10 | $1.22 | $1.56 | $1.89 |
| 2022-06-13 | $1.22 | $1.55 | $1.88 |
| 2022-06-14 | $1.21 | $1.54 | $1.87 |
| 2022-06-15 | $1.21 | $1.54 | $1.87 |
| 2022-06-16 | $1.20 | $1.53 | $1.86 |
| 2022-06-17 | $1.20 | $1.53 | $1.86 |
| 2022-06-21 | $1.19 | $1.52 | $1.85 |
| 2022-06-22 | $1.18 | $1.52 | $1.85 |
| 2022-06-23 | $1.18 | $1.51 | $1.84 |
| 2022-06-24 | $1.17 | $1.50 | $1.83 |
| 2022-06-27 | $1.17 | $1.50 | $1.83 |
| 2022-06-28 | $1.16 | $1.49 | $1.82 |
| 2022-06-29 | $1.16 | $1.49 | $1.82 |
| 2022-06-30 | $1.15 | $1.48 | $1.81 |
| 2022-07-01 | $1.14 | $1.48 | $1.81 |
| 2022-07-05 | $1.14 | $1.47 | $1.80 |
| 2022-07-06 | $1.13 | $1.46 | $1.79 |
| 2022-07-07 | $1.13 | $1.46 | $1.79 |
| 2022-07-08 | $1.12 | $1.45 | $1.78 |
| 2022-07-11 | $1.12 | $1.45 | $1.78 |
| 2022-07-12 | $1.11 | $1.44 | $1.77 |
| 2022-07-13 | $1.10 | $1.44 | $1.77 |
| 2022-07-14 | $1.10 | $1.43 | $1.76 |
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell trans... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
